Who Qualifies for GLP-1 Weight-Loss Drugs—and
Quick Facts
Who Qualifies for Prescription Weight-Loss Drugs?
US prescribing criteria generally include adults with a body mass index of at least 30, or at least 27 when a weight-related condition such as hypertension, type 2 diabetes or abnormal cholesterol is present. BMI is a screening measure rather than a complete diagnosis, so clinicians also consider medical history, previous treatment attempts, current medicines, pregnancy plans and the likelihood that treatment can be continued safely.
Semaglutide, marketed as Wegovy for chronic weight management, acts at the glucagon-like peptide-1 receptor. Tirzepatide, marketed as Zepbound, activates both glucose-dependent insulinotropic polypeptide and GLP-1 receptors. These pathways influence appetite, food intake and glucose regulation. Neither medicine is intended to replace nutrition, physical activity, sleep support or management of obesity-related conditions.
Why Are Many Eligible Adults Not Using GLP-1 Medicines?
Growing public awareness does not guarantee access. Insurance rules may require prior authorization or documentation of previous weight-management efforts, while some plans exclude obesity medicines. Out-of-pocket costs can be prohibitive, and patients may have difficulty finding clinicians who provide comprehensive obesity care and ongoing monitoring.
Clinical considerations also matter. Nausea, vomiting, diarrhea, constipation and abdominal symptoms are common with GLP-1-based treatment, particularly while doses are being increased. Product labeling includes important warnings and contraindications, and patients need individualized counseling. Concerns about injections, loss of lean mass during weight reduction, interactions with other diabetes treatments and possible weight regain after discontinuation may also affect decisions.
How Effective Are Semaglutide and Tirzepatide for Weight Loss?
In the STEP 1 randomized trial, published in The New England Journal of Medicine in 2021, adults with overweight or obesity who did not have diabetes achieved markedly greater average weight loss with once-weekly semaglutide plus lifestyle intervention than with placebo plus lifestyle intervention. The trial established that medication can add meaningful benefit to behavioral care, but it did not show that every patient will respond equally.
The SURMOUNT-1 trial, published in the same journal in 2022, found substantial dose-dependent weight reduction with tirzepatide in adults with obesity or overweight without diabetes. Trial participants received structured support and regular follow-up, conditions that may differ from routine practice. Treatment decisions should therefore focus on health improvement, tolerability and sustainable care rather than comparisons driven solely by headline weight-loss percentages.
Frequently Asked Questions
No. Certain products, including Wegovy and Zepbound, are approved for chronic weight management in eligible people regardless of whether they have diabetes. Brand names and indications matter because products containing related ingredients are not automatically interchangeable.
Weight regain can occur after treatment ends because the biological drivers of appetite and weight regulation may return. Patients should discuss long-term therapy, affordability, side effects and a maintenance plan with their clinician before starting.
Compounded medicines are not FDA-approved and do not undergo the same premarket review for safety, effectiveness and manufacturing quality. Patients should avoid unverified online products and discuss any access problem with a licensed clinician and pharmacist.
References
- WBFF. Weight-loss drugs surge in popularity, but many Americans still aren't using them. July 2026.
- US Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. June 4, 2021.
- US Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 8, 2023.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022.